PA5-21721

Pietrobono S, Anichini G, Sala C, Manetti F, Almada LL, Pepe S, Carr RM, Paradise BD, Sarkaria JN, Davila JI, Tofani L, Battisti I, Arrigoni G, Ying L, Zhang C, Li H, Meves A, Fernandez-Zapico ME, Stecca B
Nature communications 2020 Nov 17;11(1):5865

Mytych J, Sołek P, Będzińska A, Rusinek K, Warzybok A, Tabęcka-Łonczyńska A, Koziorowski M
Cells 2020 Jan 21;9(2)

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of ST3GAL1 using 30 µg of HeLa S3 lysate. Samples were loaded onto a 12% SDS-PAGE gel and probed with a ST3GAL1 polyclonal antibody (Product # PA5-21721) at a dilution of 1:500.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot using ST3GAL1 Polyclonal Antibody (Product # PA5-21721). Various whole cell extracts (30 µg) were separated by 12% SDS-PAGE, and the membrane was blotted with ST3GAL1 Polyclonal Antibody (Product # PA5-21721) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of ST3GAL1 in methanol-fixed Hep3B cells using a ST3GAL1 polyclonal antibody (Product # PA5-21721) at a 1:500 dilution.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of methanol-fixed Hep3B, using SIAT4A antibody (Product # PA5-21721) at 1:500 dilution.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis of ST3GAL1 was performed in paraffin-embedded human ovarian cancer tissue using ST3GAL1 Polyclonal Antibody (Product # PA5-21721) at a dilution of 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 Expression of ST3GAL1 in cutaneous melanomas and association with melanoma progression. a , b Box plots illustrating expression of ST3GAL1 mRNA in skin cancers ( a ) and in nevi, primary and metastatic melanoma samples ( b ). Box-plots report median (central lines), 25th and 75th percentiles (box limits), and upper and lower whiskers represent values no further than x1.5 interquartile range (IQR). Data were obtained from the analysis of the public available microarray data sets GSE7553 and GSE46517, respectively. In GSE7553: normal skin ( n = 4), in situ melanomas (MIS) ( n = 2), primary and metastatic melanomas ( n = 54), basal cell carcinomas (BCC) ( n = 15), and squamous cell carcinomas (SCC) ( n = 11). In GSE46517: nevi ( n = 9), primary melanomas ( n = 31), metastatic melanomas ( n = 73). P value was calculated by ANOVA and Holm-Sidak's test. c Genomic profile of ST3GAL1 in melanoma patients obtained from Skin Cutaneous Melanoma data set (TCGA, Provisional) using cBioportal database ( http://www.cbioportal.org ) , . In all, 23% of melanoma samples present alterations of ST3GAL1 , including gene amplification, mRNA upregulation or somatic mutations. d Immunostaining of ST3GAL1 in human melanoma tissue microarrays, including nevi ( n = 23), primary ( n = 56), and metastatic ( n = 40) malignant melanomas. Representative images of human normal skin, nevi, primary (PM), and metastatic melanomas (MM). ST3GAL1 staining was evaluated blindly and scored as negative (no sig